102 results about "Valproate Sodium" patented technology

A process for preparing divalproex sodium tablets is provided. The process comprises preparing a neutralized divalproex sodium solution by combining divalproex sodium, having a sodium valproate and a valproic acid moiety, with an aqueous solvent and a base, e.g., sodium hydroxide, the base being in sufficient amount to ensure neutralization of the valproic acid moiety of the divalproex sodium. The neutralized divalproex sodium solution is sprayed onto a pharmaceutically acceptable carrier, and processed to obtain divalproex sodium tablets.

The invention belongs to the field of animal experiment models, and discloses application of a composite high-fat forage to construct a non-alcoholic fatty liver disease rat model. The high-fat forage is composed of the following raw materials in percent by mass: 77.5% of a rat basic forage, 10% of egg, 10% of coconut oil, 2% of cholesterol, 0.5% of bile salt, and 500mg / kg / d of sodium valproate calculated according to the rat weight. After 8 weeks, rats all have typical non-alcoholic fatty live symptoms, and liver has a lot of fat accumulation along with inflammatory cell infiltration. The model establishing time is short, the success rate is high, and the composite high-fat forage is applicable to pathogenesis research induced by high-fat-diet combined medicines with liver-toxicity side effect, screening of related control measures and efficacy evaluation of treatment medicines.

The invention provides a sodium valproate crystal form III. In a diffraction pattern of powder X-ray diffraction of a crystal, characteristic absorption peaks exist at diffraction angles (2 theta) of 5.40 DEG, 6.31+ / -0.1 DEG, 7.28 DEG, 76.86 DEG and 18.10 DEG. The invention also provides a preparation method of the crystal form and a medicinal composition containing the crystal form. The sodium valproate crystal from III has high solubility and controllability, is safe and stable and provides a new preparation choice for clinical application.

The invention relates to the technical field of biochemical and provides a method for detecting sodium valproate content of blood through high performance liquid chromatography. The method comprises the steps of preparing 37.6mug / ml of a sodium valproate standard solution, sodium valproate working solutions with various concentrations, 50.2mug / ml of a hexahyl carbonic acid internal standard solution, a blank sample, a normal human blood sample and a patient blood sample; putting into a chromatographic instrument to draw chromatograms, and judging whether the blood of a patient contains sodium valproate according to the chromatograms; then drawing a sodium valproate standard curve with the chromatographic instrument according to the chromatogram of the normal human blood sample, and calculating the sodium valproate content of the blood of the patient according to a peak sodium valproate value of the chromatogram of the patient blood sample, a peak value of the hexahyl carbonic acid internal standard solution and the sodium valproate standard curve. According to the method, the problems that the chromatograms contain multiple stray peaks, the sensitivity is low, the precision is low, the cost is high, and the sodium valproate standard curve cannot be drawn are effectively solved.

A process for preparing divalproex sodium tablets is provided. The process comprises preparing a neutralized divalproex sodium solution by combining divalproex sodium, having a sodium valproate and a valproic acid moiety, with an aqueous solvent and a base, e.g., sodium hydroxide, the base being in sufficient amount to ensure neutralization of the valproic acid moiety of the divalproex sodium. The neutralized divalproex sodium solution is sprayed onto a pharmaceutically acceptable carrier, and processed to obtain divalproex sodium tablets.

The invention discloses a synthesis process for sodium valproate. The synthesis process comprises the following steps: mutually dissolving diethyl malonate and 1-bromopropane, slowly adding the obtained mixture into an ethanol solution of sodium ethoxide at a certain temperature, carrying out heating and reflux for 2 h, recovering ethanol until temperature is 110 DEG C, carrying out cooling to less than 80 DEG C, adding a certain amount of water to dissolve sodium bromide, carrying out layering to obtain a plurality of layers, then adding an aqueous sodium hydroxide solution with a concentration of 15 to 30%, carrying out hydrolysis at 60 to 70 DEG C for 3 h, then carrying out heating to recover ethanol until a gas phase temperature is 99 DEG C, carrying out cooling to less than 80 DEG C, adding hydrochloric acid for neutralization and acidifying, adding crude valproic acid to dissolve dipropylmalonic acid so as to obtain mixed acid and subjecting the mixed acid to slow heating and decarboxylation at 110 to 160 DEG C for production of crude valproic acid; and subjecting the crude valproic acid to rectification and refining, adding a certain amount of the aqueous sodium hydroxide solution for neutralization, adding toluene for reflux to bring out water, thereby allowing sodium valproate to dehydrate and crystallize and then successively carrying out filtering, washing with chloroform and drying so as to obtain finished sodium valproate. The process is safe and environment-friendly, produces good-quality sodium valproate, has low cost and is suitable for industrial production.

The invention provides a bi-path detecting card capable of simultaneously detecting carbamazepine and sodium valproate and a detecting method of the same, and belongs to the technical field of the monitoring on the blood concentration of antiepileptic drug. In the invention, a detecting window and a sample adding hole are arranged on the surface of a shell of the detecting card; a testing bar is arranged in the shell; a nitrocellulose film is adhered to the middle part of a backing board of the testing bar; a water absorbent film is adhered to one end of the backing board; a sample pad is adhered to the other end of the backing board; two segments of colloidal gold films are arranged between the water absorbent film and the sample pad in an adhesive manner; the colloidal gold films are respectively glass fiber films containing colloidal gold markers of monoclonal antibodies resistant to the carbamazepine and the sodium valproate; three separated imprint display strips are transversely arranged on the nitrocellulose film, and include a detecting strip containing carbamazepine protein conjugate, an another detecting strip containing sodium valproate protein conjugate and a quality control strip containing antibodies resistant to a rabbit or a rat; the sample pad is just opposite to the sample adding hole; and the nitrocellulose film is just opposite to the detecting window. The detecting card can be used for simultaneously detecting components of two anticonvulsants in a serum sample, and has the advantages of saved cost for detection, convenience for use, quickness in detection, high sensitivity and accuracy in result.

The invention discloses a sodium valproate crystal form II as well as a preparation method and application thereof, wherein characteristic absorption peaks appear at diffraction angles of (2theta)=6.3-6.5 DEG, 7.12-7.32 DEG, 7,3-7.5 DEG, 16.95-17.15 DEG, 18.15-18.35 DEG, 18.88-19.08 DEG and 19.17-19.37 DEG in a powder x-ray diffraction pattern of the crystal. The sodium valproate crystal form II provided by the invention has the advantages that the hygroscopicity is significantly reduced and lower water content of the product is guaranteed to ensure that the quality of the sodium valproate is more stable in storage period; while the hygroscopicity is reduced, the dissolution time of the product is significantly shortened and the dissolvability of the product is improved to ensure that the curative effect and very good safety of the sodium valproate are guaranteed in clinical application, the injection pain is also significantly relieved, compliance of patients is increased during treatment and very good clinical effect of the treatment is obtained.

The invention provides a composition comprising prostaglandin derivatives and valproic acid or a pharmaceutically acceptable salt thereof and an ophthalmic liquid formulation comprising the composition, wherein the prostaglandin derivative is preferably one of latanoprost, bemeprost, travoprost, taflurane, unoprost and latanoprostene, and valproic acid or a pharmaceutically acceptable salt thereofis preferably one of valproic acid, sodium valproate, sodium divalproate and magnesium valproate. The composition provided by the invention can synergistically reduce intraocular pressure, avoid theuse of cosolvent, and improve the safety of medicament.

The invention discloses a preparation method of a sodium valproate sustained release tablet, and belongs to the technical field of medicines. The sodium valproate sustained-release tablet disclosed by the invention consists of active medicines, namely valproic acid, sodium valproate, a flavoring agent, a framework material, a retardant, a lubricant, an adsorbent and a gastric-soluble coating premix. According to the preparation method of the sodium valproate sustained release tablet, the problem that sodium valproate in the product is not beneficial to industrial production due to extremely high hygroscopicity is solved, the hygroscopicity characteristic of the sodium valproate is utilized, the humidity in a fluidized granulator is increased to form granules in the fluidization process, the prepared granules have good flowability and tabletability, and the prepared product has good stability, has good similarity between in-vitro dissolution and original dissolution curves, and is suitable for large-scale production.

The invention discloses a pour point depressant for crude oil, a preparation method for the pour point depressant and application of the pour point depressant. The pour point depressant is prepared from the following ingredients in parts by weight: 2-15 parts of sodium 1,4-bis(1,3-dimethylbutyl) sulphonatosuccinate, 4-16 parts of polyvinyl pyrrolidone, 4-13 parts of hexadecyl dimethyl tertiary amine, 5-19 parts of sodium valproate, 5-18 parts of ammonium oxalate, 1-11 parts of nano-scale palladium borate, 400-600 parts of 10ppm-250ppm polyvinyl acid, 3-15 parts of 4-(1-methylethyl)cyclohexadiene-1-ethanol formate, 2-15 parts of polyacrylamide, 7-21 parts of cross-linker, 2-18 parts of vinylethylene carbonate, 2-12 parts of 4,4'-dimethoxytrityl chloride, 1-4 parts of 3,5-dibromomethyl toluene and 5-7 parts of sodium ethylenediamine tetramethylene phosphate. The pour point depressant for the crude oil, disclosed by the invention, is efficient and is stable in chemical property, and under the condition of low temperature, wax crystals cannot be precipitated when high-wax crude oil is transported by a pipeline; and the viscosity of the high-wax crude oil cannot be improved along with the drop of temperature, and the rheological property of the high-wax crude oil is not changed along with temperature drop.

The invention discloses a divalproex sodium orally disintegrating tablet and a preparation method thereof. The principal medicine of the orally disintegrating tablet is divalproex sodium and the accessories are microcrystalline cellulose, mannitol, lactose, polyacrylic resin II, cross linked polyvinylpyrrolidone, sodium cyclamate, menthol and aerosil. The divalproex sodium orally disintegrating tablet of the invention can effectively cure falling sickness and vesania, can prevent hemicrania and has the advantages of convenient taking, good taste, fast disintegration, quick absorption and high biological availability. The divalproex sodium orally disintegrating tablet provides convenience for old people, children or patients having difficulty in swallowing and people having inconvenience to get water.